Literature DB >> 22068554

Pancreatic autoantibodies, HLA DR and PTPN22 polymorphisms in first degree relatives of patients with type 1 diabetes and multiethnic background.

B Barone1, J R Dantas, M H Almeida, B S Anna-Gomes, M D R Bencke-Gongalves, M S Albernaz, M R Rodrigues, L Zajdenverg, R Kupfer, A Milech, M Rodacki, J E P Oliveira.   

Abstract

AIM: To evaluate the prevalence of pancreatic auto-antibodies (PAb) as well as its relationship with HLA DR B1 and PTPN22 polymorphisms in first degree relatives (FDR) of Brazilian patients with Type 1 diabetes (T1D) and multiethnic background.
METHODS: FDR of patients with T1D were interviewed and blood was sampled for PAb measurement, HLA DRB1 and PTPN22 genotyping. Genotyping was also performed in index cases.
RESULTS: In FDR (n=78), 16.7% presented at least one PAb. These individuals had a higher prevalence of HLA DRB1* 03 than others (p=0.03), without differences in PTPN22 genotyping. While the genetic profile was similar in FDR with PAb and their index cases, those without PAb had a lower frequency of HLA DR B1 * 03 than their correspondent patients (p=0.009).
CONCLUSION: In this multiethnic population, a significant proportion of FDR of T1D patients had PAb, which was associated with HLA DR B1 * 03 but not with the PTPN22 polymorphism. © J. A. Barth Verlag in George Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068554     DOI: 10.1055/s-0031-1280799

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  2 in total

1.  Improving power of genome-wide association studies with weighted false discovery rate control and prioritized subset analysis.

Authors:  Wan-Yu Lin; Wen-Chung Lee
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

2.  Prospective evaluation of glutamine and phospholipids levels in first degree relatives of patients with Type 1 Diabetes from a multiethnic population.

Authors:  D B Araujo de Pina Cabral; J R Dantas; H Skärstrand; B Barone; F Carvalho; R Tortora; A Milech; F Vaziri-Sani; J E P Oliveira; L Zajdenverg; M Rodacki
Journal:  Diabetol Metab Syndr       Date:  2015-06-10       Impact factor: 3.320

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.